|Day Low/High||140.07 / 145.76|
|52 Wk Low/High||79.88 / 193.56|
SAGE's First Oral Compound From Its Pipeline of Next Generation CNS Modulators Enters Clinical Development
Strategic Additions Broaden Organizational Capabilities as SAGE Advances Novel Therapeutics in Clinical and Late-Stage Development
The signal of activity Sage Therapeutics sees with SAGE-547 in essential tremor may turn out to be real or a mirage.
STATUS Trial of SAGE-547 is First Global Phase 3 Trial of Patients With SRSE, a Rare and Life-Threatening Seizure Disorder With no Approved Therapies
Provides FDA Agreement on Trial Design, Endpoints and Statistical Approach of the Phase 3 STATUS Trial
Only one fund category (of 20) has beaten the S&P 500 over half a decade.
Phase 3 STATUS Trial - Randomized, Double-Blind, Placebo-Controlled Clinical Trial of SAGE-547 for the Treatment of Patients With SRSE - Expected to Initiate by Mid-2015
Final SAGE-547 Super-Refractory Status Epilepticus Phase 1/2 Clinical Data to be Presented at Antiepileptic Drug and Device Trials Conference
Final SAGE-547 Phase 1/2 Clinical Data to be Presented at Annual Antiepileptic Drug and Device Trials Conference
Multiple Clinical and Scientific Milestones Anticipated in 2015
Amy Schacterle, Ph.D. Joins SAGE as Vice President of Regulatory Affairs and Quality Assurance, Erin Lanciani as Vice President of Human Resources
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.